Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID syndrome The stratification factors are HBV/HCV positive (cohort A), HIV positive (cohort B), patients with Long Covid syndrome (Cohort C), histology (squamous vs non-squamous histology), and gender (male vs female).

NCT Number	NCT05597800
Lead Sponsor	Universita di Verona
Conditions	NSCLC Stage IV, HIV, HBV, HCV, Long COVID
Enrollment	105 participants
Start Date	2023-02-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-03-30 (estimated)
Updated on ClinicalTrials.gov	2022-10-28